ERBB2 and breast carcinoma: Albeit long-term follow-up from these trials is warranted, the substantially low risk of locoregional relapses is indeed encouraging and may pave the way for future clinical trials investigating radiotherapy de-escalation strategies in stringently selected low-risk early-stage HER2+ breast cancers.